Altered expression of TSPAN2 has been reported across glioma transcriptomic and proteomic studies, and modulation of TSPAN2 influences microglial activation and cytokine signaling, processes increasingly recognized as contributors to the glioblastoma microenvironment and treatment resistance [32]. The gene discussed is TSPAN2; the disease is central nervous system cancer.